Skip to content
NASDAQ · LABORATORY ANALYTICAL INSTRUMENTS · SMALL CAP

Precipio, Inc. PRPO

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$24.0M
▲ 29.8% YoY
$-363,000
$359,000
▲ 66.2% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Our pathology services division provides specialized cancer diagnostic testing services to physicians, hospitals, and laboratories. This division generates revenue and supports the development of our expertise in oncology diagnostics. These products allow the Company to expand its reach by enabling other laboratories to benefit from the diagnostic products developed by the Company while building scalable diagnostic solutions. As of March 9, 2026, Precipio employed sixty-one (61) employees on a full-time basis and ten (10) employees as part-time. Precipio, Inc. was incorporated in Delaware on March 6, 1997. Our principal office is located at 4 Science Park, New Haven, Connecticut 06511.

Written from the business description in Precipio, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 30 March 2026. Every sentence was checked against that document before publication.

Growth

USD 24.0M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 24.0 · Net income -0.4
15M30M-15M-30M
2009201220152018202120242025
Compound annual growth
+36.7%
+31.6%
+28.7%
+1.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +31.6% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−2 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -5.0% · Net -1.5%
-500%-1000%
200920172025
ROE
FY2025 · ROE -2.7%
-50%-100%-150%
200920172025
Three returns, three denominators.

Each USD of equity lost 3 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 0.4
-5M-10M
200920172025

Total assetsUSD 21.3M
CashUSD 2.7M
Gross debtUSD 77,000.00
Net debtUSD -2.6M
Current ratio1.61×

Net debt stands at -18% of equity.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
PRPO, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.0−0.0−0.00.00.00.00.0−0.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0
EPS, diluted $−0.23−2.93−4.51−10.73−0.40−0.85−2.33−13.82−7.16−9.44−2.78−2.01−2.30−1.55−2.62−0.06−0.04
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %−2.7−32.3−38.1−59.6−44.0−77.5−137.0−163.9———−154.9−100.8−53.2−100.1−31.1−16.5
Shares out B0.000.000.000.020.020.020.010.030.010.000.010.010.010.070.050.05◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 82 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: the share count is not tagged before 2010. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityLaboratory Analytical Instruments
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image